Ireland - English - HPRA (Health Products Regulatory Authority)

mcneil healthcare (ireland) ltd - paracetamol, codeine phosphate - film coated tablet - 500/8 milligram - analgesics and antipyretics

Malta - English - Medicines Authority

mcneil products limited - buclizine hydrochloride, paracetamol, codeine phosphate - film-coated tablet - buclizine hydrochloride 6.25 milligram(s) ; paracetamol 500 milligram(s) ; codeine phosphate 8 milligram(s) - analgesics

Malta - English - Medicines Authority

mcneil products limited foundation park, roxborough way, maidenhead, berkshire sl6 3ug, united kingdom - paracetamol, codeine phosphate - film-coated tablet - paracetamol 500 mg codeine phosphate 8 mg - analgesics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mcneil products ltd - not applicable

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mcneil products ltd - codeine phosphate; paracetamol - oral tablet - 8mg ; 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mcneil products ltd - buclizine hydrochloride; paracetamol; codeine phosphate - oral tablet - 6.25mg ; 500mg ; 8mg

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: hyprolose; povidone; propylene glycol; purified talc; sodium starch glycollate type a; hypromellose; sodium starch glycollate type b; maize starch; magnesium stearate; colloidal anhydrous silica; poloxamer; glucose; titanium dioxide - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - efavirenz, quantity: 200 mg - tablet, film coated - excipient ingredients: carnauba wax; hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - stocrin is indicated for use in combination with other antiviral agents for the treatment of hiv-1 infection in adults and children (see clinical trials; use in children).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - efavirenz, quantity: 600 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium lauryl sulfate; hyprolose; lactose monohydrate; magnesium stearate; carnauba wax; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - storcrin is indicated for use in combination with other antiviral agents for the treatment of hiv-1 infection in adults and children. (see clinical trials; use in children)

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 49.7 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350; brilliant scarlet 4r aluminium lake - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.